前列腺癌管理新概念:寡转移性前列腺癌治疗的困境——透过暗色玻璃窥视
本文概述寡转移性前列腺癌在识别、治疗与管理上的争议。定期PSA监测联合PET/CT等影像技术进步使早期发现潜在初始播散和复发成为可能。近期系统综述和试验支持对寡转移灶行局部消融治疗可行且安全,局部控制率高、并发症低,但该患者队列的预后与临床相关性、局部激进治疗能否改变疾病进展自然史并获益仍存许多疑问。
要点
- 定期PSA监测联合PET/CT等影像进步有助更早识别前列腺癌潜在初始播散与复发。
- 近期系统综述和试验支持寡转移灶局部消融治疗可行且安全,局部控制率高、并发症低。
- 寡转移患者队列的预后与临床相关性、局部激进治疗能否改变自然史并获益仍存疑问。
核心结论
- 寡转移性前列腺癌的识别、治疗与管理仍存在诸多问题,局部消融治疗虽可行安全且局部控制率高、并发症低,但能否改变疾病进展自然史并使患者获益尚不明确。
研究设计与样本
- 本文为概述性综述,围绕寡转移性前列腺癌的识别、治疗与管理问题展开论述。
局限性
- 原文指出该患者队列是否具有预后和临床相关性、局部激进治疗最终能否改变疾病进展自然史并使这些男性获益仍存许多疑问。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
The management of oligometastatic prostate cancer continues to stimulate as well as vex cancer professionals since the concept was raised more than two decades ago. The use of regular prostate-specific antigen (PSA) monitoring together with advances in imaging technology such as combined positron-emission tomography (PET)/computed tomography (CT) has enable earlier identification of potential initial spread of disease and recurrence. Recent systematic reviews and trials have supported the feasible and safe delivery of local ablative therapies for oligometastatic lesions with high local control rates and low morbidity. This is very appealing not only to the clinician but hugely to the patient; however, many questions remain as to whether this patient cohort is prognostically and clinically relevant as well as ultimately if local aggressive therapies can alter the natural history of disease progression and benefit these men. This overview examines the issues for identification, treatment, and management of men with oligometastatic prostate cancer.
引用
- Khoo V. New concepts in prostate cancer management: the conundrum of managing oligometastatic disease in prostate cancer-through the looking glass darkly. Clin Radiol. 2019. PMID: 31176447. doi:10.1016/j.crad.2019.05.003
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。